Table 4.
Age, years, gender | Source of infection | Pathogen | Days of IV therapy | Agent | Microbiological response | Clinical response |
---|---|---|---|---|---|---|
Telavancin, n = 8 | ||||||
55, male |
Peripherally inserted central catheter |
MRSA |
15 |
Telavancin |
Eradication |
Cure |
55, male |
Central IV catheter |
MRSA |
14 |
Telavancin |
Eradication |
Cure |
74, male |
Peripheral IV catheter |
MRSA |
14 |
Telavancin |
Eradication |
Cure |
37, male |
Central IV catheter |
MRSA |
14 |
Telavancin |
Eradication |
Cure |
53, male |
Cellulitis, associated with a previous peripheral IV catheter |
MSSA |
12 |
Telavancin |
Eradication |
Cure |
63, female |
Central IV catheter |
MRSA |
13 |
Telavancin |
Eradication |
Cure |
56, female |
Central IV catheter |
MSSA |
15 |
Telavancin |
Eradication |
Cure |
73, female |
Peripheral IV catheter |
MSSA |
15 |
Telavancin |
Relapse |
Failure |
Standard therapy, n = 9 | ||||||
25, female |
Cellulitis |
MRSA |
15 |
Vancomycin |
Relapse |
Cure |
59, male |
Peripheral IV catheter |
MRSA |
14 |
Vancomycin |
Eradication |
Cure |
87, female |
Peripherally inserted central catheter |
MSSA |
14 |
Vancomycin |
Eradication |
Cure |
75, male |
N/A |
MSSA |
15 |
ASP |
Relapse |
Failure |
55, female |
Peripherally inserted central catheter |
MSSA |
15 |
Vancomycin |
Eradication |
Cure |
83, female |
Decubitus ulcer |
MRSA |
13 |
Vancomycin |
Eradication |
Cure |
50, female |
Central IV catheter |
MSSA |
15 |
ASP |
Eradication |
Cure |
75, male |
Central IV catheter |
MSSA |
15 |
ASP |
Eradication |
Cure |
53, male | Central IV catheter | MRSA | 13 | Vancomycin | Eradication | Cure |
ASP, anti-staphylococcal penicillin; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; N/A, not available; SAB, Staphylococcus aureus bacteremia.